Table 2.
Most frequently used medications for EIBA and EIBwA and the 2015 World Anti-Doping Agency (WADA) regulations
| Treatment | WADA rules | Notes |
|---|---|---|
| Antihistamines | Permitted | Second generation molecules should be preferred to avoid side effects |
| Leukotriene modifiers | Permitted | |
| Inhaled steroids | Permitted | |
| Systemic steroids | Prohibited in competition | |
| Beta-2 agonists | Inhaled Salbutamol (max 1600 mcg/24H), Formoterol (max 54 mcg/24H) and Salmeterol permitted | The presence in urine of salbutamol >1000 ng/mL or formoterol >40 ng/mL is presumed not to be an intended therapeutic use of the substance and will be considered as an Adverse Analytical Finding |
| All others prohibited in and out | ||
| competition | ||
| Mast-cell stabilizers | Permitted | |
| Anticholinergic agents | Permitted | |
| Immunotherapy | Permitted | SCIT should not be performed before or after physical exercise |